The role of imaging in the detection of prostate cancer local recurrence after radiation therapy and surgery

Darko Pucar, Tamar Sella, Heiko Schöder

Research output: Contribution to journalReview article

78 Citations (Scopus)

Abstract

PURPOSE OF REVIEW: The aim of this article is to review novel MRI and nuclear medicine methods for detecting and planning salvage treatment for prostate cancer local recurrence after radical prostatectomy or radiation therapy. RECENT FINDINGS: Traditional methods for detecting local recurrence (i.e., digital rectal exam or transrectal ultrasound and digital rectal exam or transrectal ultrasound-guided biopsy) have limited accuracy in determining the presence and extent of local recurrence and therefore have limited ability to guide salvage therapy. Recent studies indicate that conventional T1 and T2-weighted prostate MRI could improve the detection of recurrent prostate cancer after radical prostatectomy or radiation therapy and salvage treatment planning. Promising new sequences could further increase the accuracy of MRI. In addition, the use of technically improved PET/computed tomography scanners with new tracers like C and F choline and acetate might offer better assessment of recurrent prostate cancer than F-2-fluoro-D-deoxyglucose-PET and monoclonal antibody imaging with the prostate specific membrane antigen antibody In-capromab pendetide (ProstaScint). SUMMARY: With systemic therapies for recurrent prostate cancer after radical prostatectomy or radiation therapy being noncurative, the application of MRI and nuclear medicine modalities can help to identify patients who have isolated local recurrence amenable to salvage treatment.

Original languageEnglish (US)
Pages (from-to)87-97
Number of pages11
JournalCurrent Opinion in Urology
Volume18
Issue number1
DOIs
StatePublished - Jan 1 2008

Fingerprint

Salvage Therapy
Prostatic Neoplasms
Radiotherapy
Prostatectomy
Recurrence
Nuclear Medicine
X-Ray Computed Tomography Scanners
Deoxyglucose
Choline
Prostate
Acetates
Monoclonal Antibodies
Biopsy
Antibodies
Capromab Pendetide
Therapeutics

Keywords

  • Local recurrence
  • Magnetic resonance imaging
  • Nuclear medicine
  • Prostate cancer

ASJC Scopus subject areas

  • Urology

Cite this

The role of imaging in the detection of prostate cancer local recurrence after radiation therapy and surgery. / Pucar, Darko; Sella, Tamar; Schöder, Heiko.

In: Current Opinion in Urology, Vol. 18, No. 1, 01.01.2008, p. 87-97.

Research output: Contribution to journalReview article

Pucar, Darko ; Sella, Tamar ; Schöder, Heiko. / The role of imaging in the detection of prostate cancer local recurrence after radiation therapy and surgery. In: Current Opinion in Urology. 2008 ; Vol. 18, No. 1. pp. 87-97.
@article{b911d0c7f30842728839e9dcf55b1dee,
title = "The role of imaging in the detection of prostate cancer local recurrence after radiation therapy and surgery",
abstract = "PURPOSE OF REVIEW: The aim of this article is to review novel MRI and nuclear medicine methods for detecting and planning salvage treatment for prostate cancer local recurrence after radical prostatectomy or radiation therapy. RECENT FINDINGS: Traditional methods for detecting local recurrence (i.e., digital rectal exam or transrectal ultrasound and digital rectal exam or transrectal ultrasound-guided biopsy) have limited accuracy in determining the presence and extent of local recurrence and therefore have limited ability to guide salvage therapy. Recent studies indicate that conventional T1 and T2-weighted prostate MRI could improve the detection of recurrent prostate cancer after radical prostatectomy or radiation therapy and salvage treatment planning. Promising new sequences could further increase the accuracy of MRI. In addition, the use of technically improved PET/computed tomography scanners with new tracers like C and F choline and acetate might offer better assessment of recurrent prostate cancer than F-2-fluoro-D-deoxyglucose-PET and monoclonal antibody imaging with the prostate specific membrane antigen antibody In-capromab pendetide (ProstaScint). SUMMARY: With systemic therapies for recurrent prostate cancer after radical prostatectomy or radiation therapy being noncurative, the application of MRI and nuclear medicine modalities can help to identify patients who have isolated local recurrence amenable to salvage treatment.",
keywords = "Local recurrence, Magnetic resonance imaging, Nuclear medicine, Prostate cancer",
author = "Darko Pucar and Tamar Sella and Heiko Sch{\"o}der",
year = "2008",
month = "1",
day = "1",
doi = "10.1097/MOU.0b013e3282f13ac3",
language = "English (US)",
volume = "18",
pages = "87--97",
journal = "Current Opinion in Urology",
issn = "0963-0643",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - The role of imaging in the detection of prostate cancer local recurrence after radiation therapy and surgery

AU - Pucar, Darko

AU - Sella, Tamar

AU - Schöder, Heiko

PY - 2008/1/1

Y1 - 2008/1/1

N2 - PURPOSE OF REVIEW: The aim of this article is to review novel MRI and nuclear medicine methods for detecting and planning salvage treatment for prostate cancer local recurrence after radical prostatectomy or radiation therapy. RECENT FINDINGS: Traditional methods for detecting local recurrence (i.e., digital rectal exam or transrectal ultrasound and digital rectal exam or transrectal ultrasound-guided biopsy) have limited accuracy in determining the presence and extent of local recurrence and therefore have limited ability to guide salvage therapy. Recent studies indicate that conventional T1 and T2-weighted prostate MRI could improve the detection of recurrent prostate cancer after radical prostatectomy or radiation therapy and salvage treatment planning. Promising new sequences could further increase the accuracy of MRI. In addition, the use of technically improved PET/computed tomography scanners with new tracers like C and F choline and acetate might offer better assessment of recurrent prostate cancer than F-2-fluoro-D-deoxyglucose-PET and monoclonal antibody imaging with the prostate specific membrane antigen antibody In-capromab pendetide (ProstaScint). SUMMARY: With systemic therapies for recurrent prostate cancer after radical prostatectomy or radiation therapy being noncurative, the application of MRI and nuclear medicine modalities can help to identify patients who have isolated local recurrence amenable to salvage treatment.

AB - PURPOSE OF REVIEW: The aim of this article is to review novel MRI and nuclear medicine methods for detecting and planning salvage treatment for prostate cancer local recurrence after radical prostatectomy or radiation therapy. RECENT FINDINGS: Traditional methods for detecting local recurrence (i.e., digital rectal exam or transrectal ultrasound and digital rectal exam or transrectal ultrasound-guided biopsy) have limited accuracy in determining the presence and extent of local recurrence and therefore have limited ability to guide salvage therapy. Recent studies indicate that conventional T1 and T2-weighted prostate MRI could improve the detection of recurrent prostate cancer after radical prostatectomy or radiation therapy and salvage treatment planning. Promising new sequences could further increase the accuracy of MRI. In addition, the use of technically improved PET/computed tomography scanners with new tracers like C and F choline and acetate might offer better assessment of recurrent prostate cancer than F-2-fluoro-D-deoxyglucose-PET and monoclonal antibody imaging with the prostate specific membrane antigen antibody In-capromab pendetide (ProstaScint). SUMMARY: With systemic therapies for recurrent prostate cancer after radical prostatectomy or radiation therapy being noncurative, the application of MRI and nuclear medicine modalities can help to identify patients who have isolated local recurrence amenable to salvage treatment.

KW - Local recurrence

KW - Magnetic resonance imaging

KW - Nuclear medicine

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=37349101923&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37349101923&partnerID=8YFLogxK

U2 - 10.1097/MOU.0b013e3282f13ac3

DO - 10.1097/MOU.0b013e3282f13ac3

M3 - Review article

C2 - 18090496

AN - SCOPUS:37349101923

VL - 18

SP - 87

EP - 97

JO - Current Opinion in Urology

JF - Current Opinion in Urology

SN - 0963-0643

IS - 1

ER -